Texas Yale Capital Corp’s Regeneron Pharmaceuticals REGN Stock Holding History

Texas Yale Capital Corp’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.2M	Hold	1,924	–	–	0.03%	278
2026 Q1	$1.49M	Hold	1,924	–	–	0.04%	237
2025 Q4	$1.49M	Hold	1,924	–	–	0.05%	236
2025 Q3	$1.08M	Hold	1,924	–	–	0.03%	261
2025 Q2	$1.01M	Sell	1,924 -10	-0.5%	-$5.58K	0.03%	259
2025 Q1	$1.23M	Hold	1,934	–	–	0.05%	239
2024 Q4	$1.38M	Hold	1,934	–	–	0.06%	220
2024 Q3	$2.03M	Hold	1,934	–	–	0.09%	190
2024 Q2	$2.03M	Hold	1,934	–	–	0.1%	170
2024 Q1	$1.86M	Hold	1,934	–	–	0.08%	182
2023 Q4	$1.7M	Buy	1,934 +10	+0.5%	+$8.23K	0.08%	188
2023 Q3	$1.58M	Hold	1,924	–	–	0.07%	184
2023 Q2	$1.38M	Hold	1,924	–	–	0.07%	201
2023 Q1	$1.58M	Hold	1,924	–	–	0.08%	191
2022 Q4	$1.39M	Hold	1,924	–	–	0.08%	201
2022 Q3	$1.32M	Buy	+1,924	New	+$1.21M	0.08%	198

Other funds holding REGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Texas Yale Capital Corp's REGN Position: Q2 2026 in Review

Texas Yale Capital Corp held its Regeneron Pharmaceuticals (REGN) position steady in Q2 2026 at 1,924 shares worth $1.2M. The position accounts for 0.03% of the portfolio, ranked #278.

Texas Yale Capital Corp first reported a position in REGN in Q3 2022 and has held it in 16 quarters since. The position peaked at $2.03M in Q3 2024. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

Texas Yale Capital Corp held 1,924 shares of Regeneron Pharmaceuticals worth $1.2M as of Q2 2026.
Texas Yale Capital Corp left its Regeneron Pharmaceuticals share count unchanged in Q2 2026.
Regeneron Pharmaceuticals made up 0.03% of Texas Yale Capital Corp's portfolio in Q2 2026, its #278 holding.
Texas Yale Capital Corp first reported a position in Regeneron Pharmaceuticals in Q3 2022 and has held it in 16 quarters since.
Texas Yale Capital Corp's Regeneron Pharmaceuticals position peaked at $2.03M in Q3 2024.
1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Texas Yale Capital Corp's 13F filing for Q2 2026, filed 12 Aug 2026.